Tech Company Financing Transactions
Moderna Funding Round
Moderna, based in Cambridge, secured $450 million in funding from Alexion Pharmaceuticals, AstraZeneca and Invus.
Transaction Overview
Company Name
Announced On
1/6/2015
Transaction Type
Venture Equity
Amount
$450,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This funding round, Moderna's largest to date, will be used to further accelerate drug discovery and development across a series of drug modalities and therapeutic areas, each powered by Moderna's proprietary approach for utilizing modified mRNA to instruct native cellular machinery to make therapeutic proteins in vivo. To continue to drive these programs forward, Moderna plans immediate growth and expansion, including the addition of more than 100 industry leaders, drug development experts and scientists to its current team of 145 employees during the coming months.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Technology Sq.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
At Moderna (Nasdaq: MRNA), we are pioneering the development of a new class of drugs made of messenger RNA (mRNA).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stéphane Bancel
Chief Medical Officer
Tal Zaks
President
Stephen Hoge
VP - General Counsel
Lori Henderson
VP - Manufacturing
Juan Andres
Browse more venture capital transactions:
Prev: 1/6/2015: Glassdoor venture capital transaction
Next: 1/6/2015: Local Market Launch venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs